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Abstract 
Catuogno, M.S.; Montenegro, M.A.; Sánchez Negrette, M.; Ramirez, G.V.: Decrease of 
colonic dysplastic lesions induced by 1,2–dimetylhydrazine in butyric acid supplemented 
rats. Rev. vet. 22: 1, 13–18, 2011. The butyric acid is considered as an anticancerigenous 
compound in several models of experimental carcinogenesis. It is one of the end products 
of the non–gaseous fermentation carried out by the microbial anaerobic flora of the mam-
malian large bowel and rumen. The milk and dairy products are the main source of butyric 
acid among the animal products. The aim of this study was to determine the antitumorigenic 
effect of butyric acid on the development of dysplastic lesions, considered as unequivocal 
histologic markers of colon cancer in its initial state, in 1,2–dymethylhidrazine–treated rats. 
Six–week–old Wistar male rats with average body weight of 160 g were used. Butyric acid 
was administered diluted in drinking water at the dose of 4 mg/ml for 26 weeks. Dysplastic 
lesions in the large bowel were induced by a weekly subcutaneous injection of 1,2–dymeth-
ylhidrazine during 17 and 5 times to respective sub–groups. Less incidence of dysplastic 
lesions was observed in butyric acid–supplemented groups, both in sub–group with 17 in-
oculations and in the sub–group with 5 inoculations, compared to control sub–groups (with-
out supplementation). The dysplastic lesions also displayed variation in the mucin content 
depending on the severity of the dysplasia. We conclude that the use of butyric acid as an 
antitumorigenic compound, would be the reason for the marked decrease on the development 
of precarcinomatous lesions, considered as important precursors of colon carcinomas. 
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Resumen
Catuogno M.S.; Montenegro M.A.; Sánchez Negrette M.; Ramirez G.V.: Disminución 
de lesiones displásicas colónicas inducidas por 1,2–dimetilhidrazina en ratas suplemen-
tadas con ácido butírico. Rev. vet. 22: 1, 13–18, 2011. El ácido butírico es considerado como 
agente anticancerígeno en varios modelos de cáncer experimental. Constituye uno de los 
productos finales de la fermentación no gaseosa producida por la flora microbiana presente 
en intestino grueso y rumen de mamíferos. Entre los productos de origen animal, la leche y 
los productos lácteos constituyen una de las principales fuentes de ácido butírico. Nuestro 
objetivo fue evaluar el efecto anticancerígeno del acido butírico sobre el desarrollo de le-
siones displásicas, consideradas marcadores histológicos de cáncer de colon en sus estadios 
iniciales, en ratas tratadas con el carcinógeno 1,2–dimetilhidrazina. Fueron utilizadas ratas 
Wistar, machos con un peso promedio de 160 g a las cuales se les administró ácido butírico 
puro diluido en el agua de bebida a la concentración de 4 mg/ml, durante 26 semanas. Las 
lesiones displásicas en el intestino grueso fueron inducidas mediante una inyección subcutá-
nea semanal de 1,2–dimetilhidrazina durante 17 y 5 semanas a los respectivos grupos. En los 
lotes suplementados con ácido butírico se observó menor incidencia de lesiones displásicas 
tanto en el grupo tratado con 17 inoculaciones como en el grupo tratado con 5 inoculaciones, 
comparado con los grupos controles que no recibieron ácido butírico. Las lesiones displási-
cas también mostraron variación en el contenido de mucina dependiendo de la severidad de 
la displasia. Concluimos que la utilización de ácido butírico como agente anticancerígeno 
sería responsable de la marcada disminución del desarrollo de lesiones precarcinomatosas, 
consideradas como importantes precursores del carcinoma de colon. 
Palabras clave: rata, lesiones displásicas, cáncer de colon, ácido butírico, dimetilhidrazina.
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INTRODUCTION
Experimental models in laboratory animals give 
an excellent chance to study tumor processes and pre–
neoplastic lesions. The dysplastic lesions are precan-
cerigenous or precarcinomatous lesions considered as 
unequivocal histological markers in the initial states 
12, 17 of colon cancer 26 . These lesions are described as 
lonely entities that can appear in the colonic mucosa, 
forming part of both adenomatous 17 or carcinomatous 
lesions 26 . They are also described as aberrant crypt 
foci (ACF) 22 . The ACF are considered to be colon can-
cer preneoplastic changes based on their cellular, mo-
lecular and morphological features 3, 4 . Besides, some 
ACF with dysplasia are diagnosed as microadenoma 20 , 
adenoma 17 or in situ carcinoma 26 indicating sometimes 
that ACF presents preneoplastic lesions 27 .
Dysplastic lesions are characterized by prolifera-
tive phenomenon, gland crypts with enlarged lumens, 
marked cell basophilia, goblet cells depletion and po-
larity loss 15 . Another features mentioned include in-
crease nuclear size, nuclear pseudostratification, vari-
able amounts of mitoses and regular or irregular over-
struck tubular structures and ramifications 1 . 
In relation to molecular pathways, it is known that 
dysplastic lesions referred as adenomatous crypts or 
microadenomas, frequently show loss of heterozygos-
ity on 5q, the adenomatous polyposis coli locus 11, 21 . 
The ACF are considered to be precursors of adenoma-
tous polyps that are thought to be predecessors lesions 
of colonic carcinoma. The transition from adenoma to 
a high grade dysplasia seems to involve the P 53 gene, 
considered the guardian of the genome 10 . 
Epidemiological studies in human beings link the 
dysplastic lesion origin and colonic cancer develop-
ment with fatty foods. The involved fats are from ani-
mal source, mainly the saturated ones, which are found 
in red meat and dairy products, as well as the hydroge-
nated ones, taken out from vegetable oil. At least it ex-
plains in part the highest rate of those colon cancers in 
some south American countries 23, 28–30 . Cow milk pres-
ents several compounds considered as potential inhibi-
tors of the carcinogenesis process. Such compounds in-
clude sphingomyelin, conjugated linoleic acid, vitamin 
A, β–carotene, vitamin D, calcium and butyric acid 23 . 
In our laboratory, the effects of a dairy diet in the 
experimental colon carcinogenesis have been studied. 
In those experiments we observed fewer amounts of 
tumours in rats feeded with skimmed milk powder 
than in animals feeded with whole milk powder 23 . The 
same effects have also been noticed in other studies us-
ing cow milk and buffalo milk 24 . 
Epidemiological studies in humans and researches 
in rats have demonstrated that a fiber rich diet reduces 
colon carcinoma incidence and mortality 5 . In mammali-
ans, the microbial anaerobic flora of the large bowel and 
rumen produce short chain fatty acids (SCFAs), which 
are the acetic, propionic and butyric acids considered 
as the main non–gaseous fermentation end products 18 .
Butyric acid (BuAc) is a short chain fatty acid 
derived from fermentation of non–digestible carbohy-
drates in the colon. Such acid blocks the tumour cell 
proliferation in the colon cancer and that is the reason 
of why BuAc is thought to be the main protective com-
pound of a fiber rich diet in the colonic carcinomas 5 . 
The butyrate is the preferred energy source for the 
colonic mucosa and has been implicated in protection 
against colitis and colorectal cancer 18 . 
Some properties of the SCFAs are quick and easy 
absorption by the intestinal mucosa, and relative high 
caloric content, are metabolized by colonocytes and 
hepatocytes. They stimulate colonic absorption of so-
dium and water, and have a trophic effect on the intesti-
nal mucosa. The fermentative production of SCFAs has 
been admitted as a main mechanism in the ruminant 
intestinal digestion, whereas in human beings this re-
mains unclear. Because of this, the interest in SCFAs 
production and their effects has been growing in the 
last 10 years 7 .
All three SCFAs tend to slow proliferation, promote 
brush border enzyme activity, and inhibit both adhe-
sion to and motility across the type I collagen matrix 2 . 
They stimulate proliferation of normal crypt cells too, 
but butyrate and, in a lower degree, propionate inhibit 
colon cancer cell lines growth. At molecular level, bu-
tyrate causes histone acetylation and induces apoptosis 
and regulates the expression of various oncogenes 25 .
The purpose of this report was to determine the 
antitumorigenic effect of butyric acid, a common com-
pound found in dairy products and which is naturally 
produced as a result of the fermentation of non–digest-
ible carbohydrates, on the dysplastic lesions develop-
ment in the colon of 1,2–dymethylhidrazine (DMH) 
treated rats. 
MATERIAL AND METHODS
Animals: six–week–old Wistar male rats with an 
average body weight of 150 g, were purchased from 
Facultad de Ciencias Veterinarias (UNNE, Corrientes, 
Argentina), and housed at individual cages in a tem-
perature–controlled room at 21ºC. The animals were 
given a nutritionally adequate diet and drinking water 
ad–libitum and randomly divided into two main groups 
and sub–groups at the following manner: 
Control Group (without DMH treatment) formed 
by: Sub–group 1 (without treatment n=10) and Sub–
group 2 (supplemented with BuAc n=20).
Experimental group (with DMH treatment) 
formed by: Sub–group 3 (treated once a week 17 times 
with DMH n=20), Sub–group 4 (treated once a week 17 
times with DMH + BuAc n=20), Sub–group 5 (treated 
once a week 5 times with DMH n= 20), Sub–group 6 
(treated once a week 5 times with DMH + BuAc n = 20).
Butyric acid: BuAc was administrated in the 
drinking water at the dose of 4 mg/ml during 26 weeks 
to sub–groups 2, 4 and 6. This dose was chosen taken 
into account that the cow milk contains 0.959 mg of 
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BuAc/ml. Besides an adult rat drinks between 20 and 
30 ml of milk taking 19 to 29 mg of BuAc. Thus, the an-
imals consumed a higher concentration of BuAc than 
that found in other foods such as cow milk. 
1,2–dymethylhidrazine: dysplastic lesions were 
induced by a weekly subcutaneous injection of DMH 
during 17 weeks to sub–groups 3 and 4; and 5 weeks 
to sub–groups 5 and 6, at the dose of 20 mg/kg of body 
weight. Two weeks before the first DMH treatment pure 
BuAc 99% (Sigma–Aldrich) was administered in the 
drinking water to sub–groups 2, 4, and 6. The BuAc 
supplement was given until the sacrifice performed 26 
weeks after the beginning of the experiment. The DMH 
solution used for injection was prepared with 400 mg of 
DMH (symmetrical dimethylhydrazine dihydrochlo-
ride, Sigma Chem.Co) dissolved in 100 ml of demin-
eralized water containing 37 mg of ethylene–diamine 
tetraacetic acid. The pH was raised to 6.5 with sodium 
hydroxide. The solution was prepared every week just 
before the inoculation. 
General observations: every animal was daily ex-
amined looking for physical and behaviour. The body 
weights were weekly recorded since the beginning of 
the experiment till the sacrifice.
Sacrifice: after 26 weeks, the animals were sac-
rificed. Each one was necropsied, paying particular 
attention to the large bowel, which was removed and 
opened along its longitudinal axis. The entire large 
bowel was then fixed in 10% neutral buffered formalin 
during 24 hours. 
Study of the samples: the cleaned and fixed large 
bowels were divided into 4 segments for study: rectum, 
distal colon, proximal colon, and cecum. The bowels 
were cut in segments and the swiss–roll technique was 
performed. Then each segment was processed by the 
histological classic technique, embedded in paraffin 
wax, cut at 5 µm and stained with hematoxilin–eosin 
(HE), periodic acid–Schiff (PAS) and alcian blue (AB) 
pH 2.5. Histological slides of each large bowel seg-
ments (cecum, proximal colon, distal colon and rectum) 
were analyzed to detect, locate and typify dysplastic 
lesions. Dysplasic lesions were classified following a 
classical criterion 26 : 
• ACF with mild dysplasia: exhibit enlarged nuclei, 
loss of mucin and some nuclear stratification. 
• ACF with moderate dysplasia: exhibit pleomorphic 
nuclei, extensive nuclear stratification and greater loss of 
mucus production compared with mildly dysplastic ACF.
• ACF with severe dysplasia: or carcinoma in situ, 
exhibit highly pleomorphic nuclei that are greatly strat-
ified, a higher degree of loss of mucin, and occasionally 
increased mitotic activity 26 .
The dysplastic lesion is defined as a “precarcinoma-
tous change” and as “an unequivocal neoplastic altera-
tion of the colonic epithelium” 19 .
Statistical Analysis: to calculate the statistical dif-
ferences on the lesions incidence it was used a χ2 test 
and a simple one way analysis of variance (ANOVA) to 
compare the weight gain for each treatment group. 
RESULTS
Throughout the experience were not recorded any 
sub–group significant weight differences. The χ2 test 
showed a significant difference on the lesion incidence. 
The dysplastic lesions were found in most of the DMH 
treated animals in cecum, proximal colon, distal colon 
and rectum. A lower incidence of dysplastic lesions 
was revealed in both AcBu supplemented groups: sub 
groups with 17 inoculations (n=50) and the other with 5 
inoculations (n=14). While both sub groups just treated 
with DMH (the 17 inoculations subgroup and 5 inocu-
lations one) showed 117 dysplastic lesions and 33 le-
sions, respectively.
The amount and location of dysplastic lesions are 
registered on Tables 1 and 2. The dysplastic lesions in-
volved 1 to 10 crypts and were located on the surface, 
in the middle or filling the whole thickness of the mu-
cosa. Such lesions exhibited marked cell basophilia and 
prominent nuclei with an evident nucleoli. Depletion 
or absence of goblet cells, cell stratification and loss of 
polarity as well as gland shoot structures. This kind of 
lesion presented complete absence of mucin production 
(Figure 1). 
The dysplastic foci displayed variation in the mu-
cin content depending on the dysplasia severity. In the 
mild dysplastic lesions were observed a same depletion 
of PAS+ mucin and AB+ mucin whereas changes in the 
distribution were observed. PAS+ mucin were distrib-
uted homogeneously inside the cytoplasm. The PAS+ 
mucin was distributed with an uniform pattern inside 
Table 1. Frequency and location of dysplastic lesions 
in the segments of the large bowel. Sub–groups trea-
ted with 17 inoculations of DMH.
sub–group DMH – 17 AcBu + DMH – 17
number of rats n = 20 n = 19
number dysplastic lesions 117 50
rectum 2 (1.71%) 2 (4%)
distal colon 68 (58.12%) 34 (68%)
proximal colon 34 (29.06%) 12 (24%)
cecum 13 (11.11%) 2 (4%)
( ) Percentage over total of dysplastic lesions in each sub–
group.
Table 2. Frequency and location of dysplastic lesions 
in the segments of the large bowel. Sub–groups trea-
ted with 5 inoculations of DMH.
sub–group DMH – 5 AcBu + DMH – 5
number of rats n = 20 n = 20 
number dysplastic lesions 33 14
rectum 1 (3.03%) 1 (7.14%)
distal colon 25 (75.75%) 9 (64.28%)
proximal colon 4 (12.12%) 2 (14.28%)
cecum 3 (9.09%) 2 (14.28%)
( ) Percentage over total of dysplastic lesions in each sub–
group.
Catuogno M.S. et al.: Cáncer de colon en ratas. Rev. vet. 22: 1, 13–18, 2011
16
the cell cytoplasm (Figure 2) but AB+ mucin was lo-
cated mainly on the apical surface of the cells (Figure 
3). Few lesions with moderate dysplasia showed a slight 
tendency to loss PAS+ mucin. The severe lesions lost 
the production of PAS+ mucin as well as AB+ mucin.
DISCUSSION
The BuAc plays an important role in cell growth 
regulation, it is considered to be an inhibitor of cell 
proliferation and to strongly induce in vitro differentia-
tion for a wide variety of neoplastic cells 6 , including 
mammary gland, large bowel, rectum, liver, cervix and 
ovary 5, 12, 16 .
Furthermore BuAc induces apoptosis by modula-
tion of pro–apoptotic and anti–apoptotic gene expres-
sion as well as liberation of citochrome C, a pro–apop-
totic enzyme, from the mitochondria 16 . This type of 
apoptosis is considered p53 independent and there are 
evidences that it occurs as a final stage of the differenti-
ation process (the apoptosis p53 dependent in response 
to DNA damage occurs through another pathway op-
posite to the terminal differentiation) 6 . In another ex-
perience the BuAc arrested the growth of neoplastic 
colonocytes in G1 phase of cell cycle and blocked the 
neoplastic cell proliferation by inhibition of proto–on-
cogenes ras, src and c–myc and induction of proto–on-
cogenes c–fos and c–jun 5 .
Cyclins, cyclin–dependent kinases (cdk) and cdk 
inhibitor proteins are some of the molecular pathways 
through which BuAc causes cell cycle arrest and dif-
ferentiation to prevent the cell proliferation 16 . Some 
authors attribute BuAc anti–inflammatory effects be-
cause of its ability to induce enzymes (i.e. transgluta-
minase) able to promote the mucosal growth 7 . In spite 
of the properties previously mentioned, some studies 
do not support a chemopreventive effect. There are 
opinions that disagree respect to differences in the in 
vivo and in vitro studies, time of BuAc administration 
as well as the amount and source of BuAc used 16 .
Experimental works have used sodium butyrate 
as a BuAc source; it was administered by luminal in-
stillation and oral consumption at high concentration. 
Some results have shown promoter effects whereas 
other ones present anticancerigenous effects 13 . Trying 
to demonstrate that the responsible of the colon can-
cer increase in rats was sodium and not the butyrate 
consumption, some studies tried a tributyrin (a neutral 
short chain fatty acid triglyceride) supplementation. In 
that opportunity differences in focal dysplastic areas or 
colonic tumours have not been observed 8 . 
In the present experience, using pure BuAc diluted 
in drinking water, without sodium and esterification, 
was observed an important decrease of dysplastic le-
sions, considered pre–neoplastic lesions and histologi-
cal markers of colon cancer, compared with the two-
fold found in sub–groups DMH–treated without BuAc 
supplementation. 
The decrease of precarcinomatous lesions develop-
ment could due to the pure AcBu use at high concentra-
tions during a long time exposure. These observations 
Figure 1. Colon. Severe dysplastic foci located on 
the mucosa surface. Pseudopapilar formation, loss of 
mucin production, hyperchromatic nuclei, numerous 
mitotic figures and stratified nuclei. HE, 10x. 
Figure 2. Colon. Crypt foci with mild dysplasia. PAS 
staining demonstrate a remarkable mucin depletion 
compared with surrounding crypts (normal ones are 
shown on the bottom of the picture). PAS, 40x. 
Figure 3. Colon. Crypt foci with mild dysplasia. AB 
pH 2.5 staining showing the AB+ mucin is distributed 
almost exclusively in the apical part of the colonocyte. 
AB, 40x.
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agree with investigations which support the fact that 
the BuAc is an inhibitor of cell proliferation 6 , as well 
as tumor cell proliferation in colon cancer 5 .
Respect to the distribution of dysplastic lesions in 
large bowel segments, we observed less development 
of lesions in cecum of sub–groups treated with more 
DMH doses. That observations are coincident to ex-
perimental works made with molybdenum and tung-
sten, as well as with dairy diets, in which cecum was 
the large bowel segment that shown less amount of tu-
mours 14, 23 . Taking into account the results obtained by 
our research group, we could consider that the BuAc 
would be the responsible for the marked development 
decrease of precarcinomatous lesions considered as im-
portant precursors of colon carcinomas. 
Besides, we observed AB+ mucin predominance in 
lesions with moderate dysplasia, as well as total mucin 
depletion in severe lesions and carcinomas according 
with other works, reflecting a possible early malignant 
transformation 9 .
At the same time in the present study we observed 
some mild dysplastic lesions with an irregular distri-
bution of the mucin. A few lesions presented an ho-
mogeneous distribution of PAS+ mucin inside the cell, 
whereas AB+ mucin had a tendency to locate mainly 
on the apical area of the cells. This findings should be 
study further in the future to determine its importance 
in the early diagnosis of lesions with malignant trans-
formation potential. 
This data support the theory that several diet com-
ponents play an important role on the development of 
both cancer precursor lesions and colon cancer in rats. 
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